Shares of Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $2.93, but opened at $2.81. Curaleaf shares last traded at $2.96, with a volume of 30,407 shares.
Wall Street Analyst Weigh In
Several analysts recently weighed in on the company. Cormark upgraded Curaleaf from a "hold" rating to a "moderate buy" rating in a report on Friday, August 8th. Canaccord Genuity Group raised Curaleaf to a "strong-buy" rating in a research report on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Strong Buy".
Check Out Our Latest Analysis on CURLF
Curaleaf Trading Down 2.5%
The company has a 50 day moving average price of $2.89 and a 200 day moving average price of $1.69. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of -8.93 and a beta of 0.71. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.70 and a current ratio of 1.47.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative return on equity of 14.61% and a negative net margin of 18.08%. On average, research analysts expect that Curaleaf Holdings, Inc. will post -0.25 earnings per share for the current year.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.